Market closed

Editas Medicine/EDIT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Ticker

EDIT
Trading on

Industry

Biotechnology

Employees

265

Editas Medicine Metrics

BasicAdvanced
$257M
Market cap
-
P/E ratio
-$2.36
EPS
2.00
Beta
-
Dividend rate
$257M
2
$11.69
$3.10
2M
3.854
3.76
8.842
16.68
-28.73%
-61.23%
3.814
1.11
1.11
-1.49
247.04%
-20.32%
-6.17%
-2.92%

What the Analysts think about Editas Medicine

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Editas Medicine stock.

Editas Medicine Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Editas Medicine Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy EDIT

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Editas Medicine stock?

Editas Medicine (EDIT) has a market cap of $257M as of October 10, 2024.

What is the P/E ratio for Editas Medicine stock?

The price to earnings (P/E) ratio for Editas Medicine (EDIT) stock is 0 as of October 10, 2024.

Does Editas Medicine stock pay dividends?

No, Editas Medicine (EDIT) stock does not pay dividends to its shareholders as of October 10, 2024.

When is the next Editas Medicine dividend payment date?

Editas Medicine (EDIT) stock does not pay dividends to its shareholders.

What is the beta indicator for Editas Medicine?

Editas Medicine (EDIT) has a beta rating of 2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.